Skip to content
Clinical Trials – home

Ospedale dell'Angelo di Mestre

Verified siteinfo

Italy Via Paccagnella 11, Mestre - Venezia, Italy

  • 6 trials recruiting
  • Acute myeloid leukaemia · Acute lymphocytic leukaemia · Acute respiratory distress syndrome
  • Adult patients

About Specializations

Ospedale dell'Angelo di Mestre in Mestre - Venezia, Italy specialises in clinical trials of conditions such as Acute myeloid leukaemia, Acute lymphocytic leukaemia, Acute respiratory distress syndrome, Chronic myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Medicine

The medical center is at the forefront of Respiratory Medicine, focusing on innovative treatments for chronic respiratory conditions. The center's research is pivotal in enhancing the understanding and management of diseases such as Chronic Obstructive Pulmonary Disease (COPD).

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Interstitial Lung Disease

Through cutting-edge clinical trials, the center is advancing therapeutic strategies that significantly improve patient outcomes and quality of life.

Cardiopulmonary Research

Specializing in Cardiopulmonary Research, the center is dedicated to exploring the intricate relationship between cardiac and pulmonary health. This research is crucial for developing comprehensive treatment plans for patients with overlapping heart and lung conditions.

  • Heart-Lung Interactions
  • Pulmonary Hypertension
  • Cardiac Rehabilitation

The center's work in this field is instrumental in creating integrated care models that address the complex needs of patients with cardiopulmonary diseases.

Pharmacological Innovations

With a strong emphasis on Pharmacological Innovations, the center is pioneering the development of new drug therapies. This includes the evaluation of combination therapies that offer enhanced efficacy and safety profiles for patients with chronic conditions.

  • Combination Drug Therapies
  • Inhalation Therapies
  • Personalized Medicine

The center's contributions to pharmacology are transforming treatment paradigms, offering hope and improved health outcomes for patients worldwide.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Paccagnella 11Mestre - VeneziaItaly
Recruiting now
6 trials
Conditions studied
9
Partner status
Verified site

More sites in Mestre - VeneziaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

14 clinical trials

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Gilteritinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study of Azacitidine and Drug Combination Before Stem Cell Transplantation in Patients with High-Risk Myelodysplastic Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study of Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study on Early Treatment Intensification for Acute Myeloid Leukemia with FLT3 Mutation Using Cytarabine, Midostaurin, and Daunorubicin Hydrochloride for Patients with Low Chemosensitivity

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Graft versus host disease

Not yet recruiting

A study to evaluate the effectiveness of MC0518 (mesenchymal stromal cells) in adults with acute graft-versus-host disease that has not responded to steroids and ruxolitinib

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mesenchymal Stromal Cells, Ex Vivo Cultured
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Ospedale San Raffaele S.r.l.

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study of inotuzumab ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.